Device and drug makers keep paying doctors disciplined for misconduct

Thousands of physicians who have been disciplined for serious misconduct, like having sex with patients, are still getting paid by pharmaceutical and medical device companies to act as advisers or promotional speakers, according to an analysis from ProPublica.

In one example, Kalamazoo, Michigan-based device maker Stryker Corporation paid San orthopedic surgeon Mohammad Diab, MD, more than $16,000 in consulting and travel fees, even though he had been suspended from practice for 60 days, required to seek psychological treatment and put on seven years’ probation by California’s medical board. Diab had been disciplined for a two-year sexual relationship with a patient and is still required to have a third party present while seeing female patients.

The company is one of 400 identified by ProPublica as paying more than 2,300 physicians who have been disciplined by state medical boards in California, Florida, New Jersey, New York and Texas. Of those 2,300, at least 40 physicians had their licenses revoked or suspended.

"I think it’s crystal clear that their fiduciary duty is not to educate physicians and make public welfare better. It’s to sell a product,” said Charles Rosen, MD, co-founder of the Association for Medical Ethics. “I think they’d pay the devil if no one knows and he sells a lot.”

For more on ProPublica’s findings, click on the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.